Oncology

Latest News

AJMC Q&A with Danny Nguyen, MD | Background image credit: ipopba - stock.adobe.com

Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD

By Laura Joszt, MA
Danny Nguyen, MD

September 15th 2025

The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.

The use of miRNA in situ hybridization shows clear subtype-specific miRNAs, which the authors said warrant further investigation. | Image credit: CrazyJuke - stock.adobe.com

miRNA Profiling May Unlock SCLC Biomarkers

By Jared Kaltwasser

September 13th 2025

Value-Based Care Veterans, Surprised by EOM Results, Ponder Next Move

Value-Based Care Veterans, Surprised by EOM Results, Ponder Next Move

By Mary Caffrey

September 11th 2025

FDA | Image credit: Postmodern Studio.jpeg

FDA Approves Selumetinib for Children With NF1 and Inoperable Tumors

By Pearl Steinzor

September 10th 2025

Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC

Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC

By Alana Hippensteele, MA

September 8th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

September 16th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

September 16th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

August 23rd 2013

Early Results Robust for New Immunotherapy Agent

Anita T. Shaffer

August 23rd 2013

More Genetic Screening Needed for African-American Breast Cancer Patients

Lauren M. Green

Bruce Feinberg, DO, Discusses Cost Effective Cancer Treatment

August 22nd 2013

Bruce Feinberg, DO, Discusses Cost Effective Cancer Treatment

Bruce Feinberg, DO, Vice President and Chief Medical Officer, Cardinal Health Specialty Solutions, says cancer treatment is more than clinical guidelines, protocols, or individual drugs.

August 21st 2013

Current Issues in Breast Cancer Treatment: Chernew Leads Discussion with Swain, Newcomer on New Agents, Cost of Care

August 21st 2013

Sequester Forcing Chemo Treatments into Hospital Settings, Costing Taxpayers More in the End

The federal sequester trims Medicare payments for cancer patients receiving chemotherapy in doctors' offices in an effort to save the government money. Instead, it will end up costing more in the long run, according to the president of the American Society of Clinical Oncology (ASCO).

August 21st 2013

Panel Discusses Costly New Oncology Drugs; Study Address Cancer Drug Shortages

Although researchers have made powerful new targeted treatment options available to oncologists who treat breast cancer patients, options such as pertuzumab are associated with high costs which raises questions about access as payers assess the value of treatment.

August 20th 2013

Sequester Forcing Chemo Treatments into Hospitals Costing Taxpayers More in the End

Stanton R. Mehr

August 19th 2013

Drug Shortages Persist in Wake of Surveys

Beth Fand Incollingo Mary K. Caffrey

August 19th 2013

Managed Care Experts and Oncologists Discuss Reimbursement, Access Issues Associated with Expensive New Cancer Therapies

Expert panel convened by the American Journal of Managed Care provides insight into the challenges faced by clinicians and payers when administering cutting-edge cancer medications.

August 19th 2013

Changing the Cancer Landscape

Since the rise of genetics and advanced molecular biology, cancer research is a field that has become almost as obsessed with understanding aberrant metabolism as it is with devising therapies.

Michael Kolodziej Says Provider-Payer Connections Key in Quality, Cost-Effective Cancer Care

August 15th 2013

Michael Kolodziej Says Provider-Payer Connections Key in Quality, Cost-Effective Cancer Care

In order to deliver quality and cost-effective cancer care, Michael Kolodziej, MD, Aetna's national medical director for oncology strategies, says that providers need to get better connected with payers.

August 12th 2013

Cost of Care for Malignant and Benign Renal Masses

Aviva G. Asnis-Alibozek, PA-C Michael J. Fine, MD Paul Russo, MD Trent McLaughlin, BSc(Pharm), PhD Eileen M. Farrelly, MPH Norman LaFrance, MD William Lowrance, MD, MPH

Methods for better identifying malignant versus benign disease before nephrectomy could provide significant benefits to patients and payers.

August 8th 2013

Health Reform Will Cost Cancer Patients

In an effort to offset cost increases associated with the Affordable Care Act (ACA), the Obama administration intends to expand hospitals' access of the 340B discount drug plan. While the expansion may sound promising to some, many others worry that the program will threaten the quality of care, as increased participation risks higher potential for abuse. Even worse, the 340B program will likely rise the cost of cancer care.

August 8th 2013

Lung Cancer Pattern Predicts Recurrence

For patients with early-stage lung adenocarcinomas, the histological pattern of the tumor predicts the risk of recurrence and might help guide surgical decisions.

August 1st 2013

Narrowing Physician Access Puts Pharma in a Bind

Oncologists have a reputation to maintain - and according to the latest report from ZS Associates, when it comes to fortifying against pharmaceutical sales representatives, the specialty remains characteristically hardboiled for the second year in a row.

July 30th 2013

Panel Backs Lung Cancer Screening for Smokers

For the first time, government advisers are recommending screening for lung cancer, saying certain current and former heavy smokers should get annual scans to cut their chances of dying of the disease.

Segment 7- Healthcare System Challenges

July 29th 2013

Segment 7- Healthcare System Challenges

Panelists agreed that the cost of the new agents discussed to treat melanoma will be a challenge, just as the cost of healthcare as a whole in the United States is a major challenge.

Segment 6- Competition in the Marketplace

July 29th 2013

Segment 6- Competition in the Marketplace

Dr Fendrick asked panelists what they think about the idea of centers of excellence for specific cancers and an evidence-based steerage.

Segment 5- New Payment Models in Oncology

July 29th 2013

Segment 5- New Payment Models in Oncology

It's very, very complex to try to envision how you would come up with a single payment for an episode and not have a thousand different types of episodes in order to capture the heterogeneity of these diseases and the cost, said Dr Malin when asked to discuss the bundled payment method in oncology.

Segment 4- Nonadherence Caused by a Lack of Access

July 29th 2013

Segment 4- Nonadherence Caused by a Lack of Access

In this portion of the panel discussion, Dr Fendrick asked the panel whether or not they have noticed cost-related lack of access or nonadherence with the new agents being discussed.

Segment 3- How Payers Will Access the Value of New Agents

July 29th 2013

Segment 3- How Payers Will Access the Value of New Agents

Dr Weber said that despite all of the newer agents in development, the NCCN still offers comprehensive guidelines for the treatment of melanoma.

Segment 2- Emerging Immunotherapies for the Treatment of Metastatic Melanoma

July 29th 2013

Segment 2- Emerging Immunotherapies for the Treatment of Metastatic Melanoma

Dr Ribas opened this segment by discussing the new immunotherapy agents used in the treatment of metastatic melanoma. Specifically, he discussed the agents vemurafenib (Zelboraf), dabrafenib (Taflinar), and trametinib (Mekinist).

Segment 1- Introduction and Therapeutic Overview

July 29th 2013

Segment 1- Introduction and Therapeutic Overview

Panel moderator and AJMC co-editor-in-chief Dr Mark Fendrick introduced panelists Jennifer Malin, MD, PhD, manager and medical director of oncology, WellPoint; Jeffrey Weber, MD, PhD, senior member, H. Lee Moffitt Cancer Center Director, Donald A. Adam Comprehensive Melanoma Research Center; and Antoni Ribas, MD, PhD, Jonsson Comprehensive Cancer Center, UCLA.

July 22nd 2013

More Evidence Not All Prostate Cancers Need Treatment

In a study of older men who had died from causes other than prostate cancer, almost half were found to have prostate tumors. And up to half of those tumors detected on autopsy would have qualified for treatment had doctors known about them while the men lived, though none had been the cause of death.

July 19th 2013

Lung Cancer Screening Most Useful in High-risk People

Using low-dose CT scans to screen high-risk patients for lung tumors is far more effective at preventing lung cancer deaths than scanning those at low risk, according to a new analysis of over 53,000 volunteers.

Segment 5: The Role of Companion Diagnostics/The Effect of New Payment Models

July 18th 2013

Segment 5: The Role of Companion Diagnostics/The Effect of New Payment Models

In the final segment, panelists examine the use of companion diagnostics to determine proper patient utilization. Dr. Chernew asks if the required diagnostic testing is being appropriately used and if they are being covered by payers.

Segment 4: Reimbursement and Clinical Pathways

July 18th 2013

Segment 4: Reimbursement and Clinical Pathways

This segment of the panel discussion takes a closer look at the episode of cost for a patient going to a hospital versus a private office setting. Panelists agree that the cost of hospital care is not that much greater than in the office.

Segment 3: How Payers are assessing the Value of New Agents

July 18th 2013

Segment 3: How Payers are assessing the Value of New Agents

Dr. Chernew asks the panelists how payers address the value of these costly combination therapies when there are less expensive options available. Dr. Newcomer says that the drugs being discussed are, in fact, having a significant clinical effect.

Segment 2: Overview of Results from EMILIA and MARIANNE Trials

July 18th 2013

Segment 2: Overview of Results from EMILIA and MARIANNE Trials

In this clip, Dr. Swain and Dr. Newcomer discuss the results from the EMILIA trial. Dr. Swain notes that the survival benefit with the use of TDM-1 was five months.

Segment 1: Introduction and Patient Population

July 18th 2013

Segment 1: Introduction and Patient Population

Moderator and AJMC co-editor-in-chief, Dr. Michael Chernew delivers a brief overview of the discussion. The discussion focuses on the use of trastuzumab emtansine (Kadcyla) and pertuzumab (Perjeta). Panelists address the patient populations for the two agents and identify which are eligible to take the targeted therapy.

...

173 174 175 176 177 178 179 180 181

...

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions